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cines in the public offer. Here, we analysed the impact of these
new medicines ﬁnanced by the Spanish NHS over the period
1996–2003, as a continuation of a previous one. METHODS: A
retrospective analysis has been made, selecting new medicines.
These have been classiﬁed following the degree of therapeutic
innovation at the moment of authorisation, according to two 
criteria, the Ministry of Health and Consume (MHC) and the
Drug Information Centre of Andalusia Autonomous Commu-
nity, (CADIME). Consume data were provided by the MHC
database and was expressed as Price for sale Direct to Customer,
tax-free (PDC), by means of millions of Euro (M€). The rapid
introduction of new medicines into the clinical practice (next to
one-hundred top) and the evolution of the consumption were 
the indicators used. RESULTS: The total number of new drugs
marketed during the period of the study was 113. From those,
20 are next to one-hundred top in the ﬁrst year after authorisa-
tion. None of them were categorised as “an exceptional thera-
peutic novelty”. Most were drugs with “non o very small
therapeutic improvement” or “insufﬁcient clinical evidence”
according to the MHC and CADIME classiﬁcation, respectively.
Different status of classiﬁcation was found in more than six of
the 20 new drugs. When analysing new drug consumption, it
detected that their quote is superior to 1.9%, in average, in rela-
tion to the public annual consumption. CONCLUSIONS: The
market size, devoted to recently introduced medicines with high
prices, is important. This is not in agreement with their limited
therapeutic innovation, being even least when CADIME classiﬁ-
cation is considered. Nevertheless, a notable decrease in the
number of “innovator” drugs introduced from the year 2001
was observed.
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OBJECTIVES: To compare willingness to pay (WTP) with out
of pocket (OoP) payments of the Greek population for primary
and secondary health services utilization. METHODS: A 
telephone survey was conducted in 2003, covering a national
random sample of 1000 participants questioned regarding their
additional WTP and OoP actual payments, for a 12 month
period, in order to improve their provision of health services in
terms of NHS responsiveness and access to health care.
RESULTS: A total of 95.6% respondents were compulsory
insured, 55.8% of WTP respondents were male, 53.8% of non
WTP female. Mean age of WTP respondents was 42.1 years. A
total of 63% urban residents, 13% semi-urban and 23.8% rural.
Twenty percent (20%) of those who declared WTP had an
income per month from 900 to 1500€, 14.7% from 501 to 900€,
20% from 1501 to 3000€ and the rest (37.8%) had an income
over 3001€. Of those who denied WTP, only 16.4% had spent
nothing as OoP payments for health services utilization during
the last year, 46.9% spent up to 150€, 14.2% spent from 151
to 300€, 8% from 301 to 600€, 6.4% from 600 to 1500€ and
2.3% over 1501€. According to the WTP amount already
declared, 62.8% of those willing to pay from 0 to 50€ had actu-
ally spent approximately a total of 150€ for health services uti-
lization during the last 12 months, while 100% of those willing
to pay from 601 to 900€ had only spent up 150€. CONCLU-
SIONS: A total of 70.8% of respondents declared non WTP for
improving their access and utilization of primary and hospital
care. Among the respondents who denied WTP, 83.6% declared
OoP actual payments starting from 150 to 1500€ per year. Our
ﬁndings may reﬂect the difference between revealed and stated
populations’ preferences.
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OBJECTIVES: The objective of the study was to identify differ-
ent GP’s practicing proﬁles, in order to better understand the way
French GP’s react to governmental measures to contain cost or
to increase quality of care. METHODS: We constructed a large
database about of 4700 GP’s from 2 French regions (Aquitaine
and Burgundy) for the year 2000. Variables described physicians’
volume and structure of medical activity (ofﬁce consultations,
home visits, medical procedures, prescriptions of pharmaceuti-
cal, lab tests and X-rays examinations), income level, personal
characteristics (age, gender, speciality, localisation, contractual
status with health insurance), practice characteristics (size, 
structure by age, percentage of hospitalised patients, etc.) and
socio-economic characteristics of the geographical environment
(physicians density, distance to the nearest hospital, unemploy-
ment rate, urban or rural town). The database was analysed
though a variety of statistical methods including cluster analysis
and econometric tests. RESULTS: Four different homogeneous
groups were identiﬁed, each of them relating physicians’ level of
activity to their socio-economic status. In group 1 for instance,
GP’s have a high level of activity (2340 patients and 9300 con-
sultations in average), 46% of them practice in rural areas and
only 4% are women. Conversely, physicians in group 4 have 
a low level of activity (1050 patients, 2400 consultations in
average), 75% are located in urban areas and 44% are women.
Econometric tests allow discriminating the main determinants of
multidimensional medical activity between rural and urban GP’s.
CONCLUSIONS: The way GP’s exert medicine is not uniform.
The level and the type of medical activity greatly vary among
physicians. Individual factors as well as characteristics of the
socio-economic environment greatly explain these differences.
An immediate consequence is that any cost-containment measure
which applies uniformly to all GP’s, such as regulating fees, 
necessarily results in different outcomes according to the type of
physicians’ category.
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OBJECTIVES: To highlight the importance in establishing age
and gender bands with the aim of explaining the level of phar-
maceutical expenditure of each Primary Health Care Team
(PHCT). METHODS: Thanks to the advances of information
systems and the introduction of the Personal Health Card, it has
been possible to calculate the cost per inhabitant (according to
age and gender) taking into account the expense generated
through prescriptions produced by inhabitants assigned to the
Public Health System (Central Register of Insured). RESULTS:
According to some established criteria, 20 bands have been
determined. It is proved that 10% of the population is concen-
trated in the 67–77 year old band and the expenditure that it
generates is 33% of the total expense. However, the 9–12 year
old and 33–39 year old bands together (15% of the population)
only represent 3.8% of the total expense. Gender is also a rele-
vant variable. Women have a higher level of expense than men
for ages comprised between 21 and 72 and for those above 89
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years old. There are alternations in the maximum values for
gender in the 0 to 20 years old band. CONCLUSIONS: This
study reﬂects the need to determine an optimum number of
bands; that is, to add the information in some speciﬁc intervals
that allow us to carry out an efﬁcient analysis without losing the
necessary perspective in order to obtain related conclusions with
the aim of the study. It proves that a previous analysis is essen-
tial to evaluate the behaviour of the cost per inhabitant of a
PHCT.
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OBJECTIVES: To organize and classify existing Canadian health
information databases into a searchable repository that will
assist in identifying and assessing Canadian data available for
health outcomes and related research. METHODS: The identi-
ﬁcation of Canadian health information databases began with a
structured search strategy involving Medline (PubMed, OVID);
Internet search engines; web sites of a number of organizations,
universities and government bodies; and personal communica-
tions. Canadian databases with data from the year 2000 and
onwards were included. Databases were assigned to one of four
basic types (Administrative, Registry, Surveillance and Survey)
and further classiﬁed in a hierarchical structure using categories,
sub-categories and low-level terms. The three high-level cate-
gories were Medical Condition (MC), Population Health (PH)
and Health Services Utilization (HSU). Approximately 20% of
the identiﬁed databases were further proﬁled in detail, with
recording of information on an additional 20 variable ﬁelds
including sample size, data collection methods and data quality.
RESULTS: The creation of a classiﬁcation structure fully char-
acterized the breadth and scope of the 255 unique databases 
initially identiﬁed. By database type, the largest proportion of
databases was classiﬁed as survey (34%; n = 87), followed by
administrative (28%; n = 72), registry (22%; n = 56) and ﬁnally
surveillance (16%; n = 40). By non-exclusive database category,
most were classiﬁed as PH (n = 140), followed by HSU (n = 116)
and ﬁnally MC (n = 114). Canadian health databases were found
to provide information across a wide range of clinical conditions,
particularly those related to high disease burden areas. In addi-
tion, they provided health utilization and determinant data.
Some data gaps were recognized, such as environmental expo-
sure data, data identifying speciﬁc subpopulations, and infor-
mation needed to fully assess data quality. CONCLUSIONS:
Classifying existing Canadian health information databases
within a single, organized register is expected to provide an effec-
tive research tool in the planning of health outcomes and related
research.
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OBJECTIVES: Parameters of central tendency (mean) are often
estimated in budget impact assessment (BIA) with less emphasis
on parameters of spread (variance); critical to ﬁxed funding (FF)
policies (e.g. envelope systems) is accuracy of the estimate and
maximal precision. The complexity and diversity of the hospital
pathology mix and its treatment are the main theoretical hurdles
encountered. In this analysis, the variance of the drug treatment
reimbursement cost was investigated on the Main Diagnostic
Code (MDC) and the All Patients Reﬁned Diagnosis Related
Groups (APRDRG)-level. The aim was to select low cost 
variance diagnoses which would enhance precision in FF.
METHODS: Belgian hospitals register admission data in
minimum basic data sets (MBDS): we extracted anonymous data
from stays of 21 peripheral Flemish hospitals (during 2002).
MBDS contains ICD-9-CM codes, performed procedures, stay
parameters (e.g. risk of mortality), patient characteristics (age,
gender) and drug utilization data with the national insurance
cost. Data were analyzed in SPSSWIN® 12.0. RESULTS: The
database contained 368,618 unique stays. On MDC-level, the ﬁt
between mean cost and variance was merely a non-linear rela-
tionship; the MDC’s cardio-vascular (CV) disease, myelopro-
liferation & neoplasms, infectious disease and liver disease
exhibited a linear relationship with r2 > 0.90; in these MDC’s
low mean cost pathologies also allow ﬁxed funding. On
APRDRG-level, increased cost variance probably reﬂects
increased drug utilisation variability and/or heterogenicity in
drug pricing. llustrative examples: the ratio of mean cost for
cesarean (95€) to vaginal (27€) delivery is about 4 but the ratio
of variances exceeds 10. In the CV area, the corresponding ratios
for heart failure (269€) to angina (104€) are respectively 2.5 and
8. CONCLUSIONS: Reducing mean cost is important to BIA
but to FF reducing cost variance is essential in order for the
funding to be in line with the resources used.
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OBJECTIVES: The Medicare Prescription Drug, Improvement
and Modernization Act (MMA) of 2003 requires the General
Accounting Ofﬁce (GAO) to conduct surveys in 2004 and 2005
to determine the hospital acquisition cost for speciﬁed outpatient
drugs. The Centers for Medicare and Medicaid Services (CMS)
will use the survey data to set hospital outpatient drug payment
rates for 2006. This study explores the potential impact of poor
study design on 2006 hospital outpatient prospective payment
system (OPPS) drug payments. METHODS: Various methods of
recording acquisition cost were collected from hospital systems
and categorized. Past CMS and GAO discussions of acquisition
cost were identiﬁed and accumulated in an indexed database.
Findings from the hospital sources and the governmental sources
were compared and underlying assumptions examined with a
view toward predicting the GAO approach to determining hos-
pital drug acquisition cost. RESULTS: The hospital survey
revealed signiﬁcant variation in how acquisition cost is deﬁned
and recorded in hospital pharmacies. The most common method
reported was a percentage of average wholesale price (AWP). The
next most common method reported was actual acquisition cost
at a certain point in time, updated quarterly. Constantly updated
acquisition cost was rare, due to the required information tech-
nology. When entries in the indexed database of CMS and GAO
discussions of acquisition cost were compared to the hospital
